The Medicines and Healthcare products Regulatory Agency has officially welcomed the sentencing of Kenneth Harrison, the co-founder of medical supply company Medicina Ltd, following a landmark enforcement action concerning the unlawful distribution of unapproved and invalidly certified medical devices to National Health Service hospitals and private healthcare facilities across the United Kingdom. Harrison was handed a three-year prison sentence at Manchester Crown Court on September 23, 2026, alongside mandatory community service and a formal disqualification from holding company directorships.
The sentencing marks a critical milestone in a protracted regulatory and criminal investigation that spanned more than a decade. The case centers on the systematic distribution of vital medical equipment—including enteral feeding pumps, gastrostomy button devices, and blunt fill needles—bearing fraudulent or invalid CE markings. These regulatory stamps of approval, which at the time indicated conformity with European Union health, safety, and environmental protection standards, falsely assured clinicians and procurement officers that the devices had undergone rigorous safety evaluations.
The illicit supply chain compromised the integrity of medical procurement within the UK healthcare sector, leaving hospitals inadvertently reliant on equipment that lacked verified regulatory oversight. While the primary criminal proceedings against Harrison have concluded with his custodial sentence, related corporate entities, including Medicina Ltd itself, face ongoing legal ramifications, with sentencing for the company pending and financial confiscation proceedings actively underway.
Chronology of an Investigation: From 2013 Concerns to 2026 Prosecution
The complex legal saga that culminated in the autumn of 2026 began thirteen years prior, rooted in routine regulatory vigilance that uncovered alarming discrepancies in medical device compliance.
In 2013, initial concerns regarding the regulatory status and documentation of products distributed by Medicina Ltd were flagged to regulatory authorities. The anomalies prompted the MHRA to launch a preliminary inquiry, which quickly expanded in scope as investigators discovered systemic issues relating to the validity of the CE certifications attached to several high-utilization clinical products.
By the mid-2010s, the inquiry transitioned into a formal criminal investigation spearheaded by the MHRA’s specialized Device Compliance Unit. Investigators methodically traced the lifecycle of the compromised medical devices, analyzing procurement contracts, regulatory filings, and internal corporate communications within Medicina Ltd. The probe revealed that the company had continued to distribute devices despite knowing—or having substantial reason to know—that the CE marking documentation was invalid, thereby circumventing the statutory controls mandated to safeguard patient health.
The evidentiary burden compiled by the MHRA was subsequently handed over to the Crown Prosecution Service, leading to formal charges being authorized and announced in July 2026. Following legal proceedings, the case reached its courtroom climax at Manchester Crown Court. On September 23, 2026, Judge Timothy Smith delivered the verdict: a three-year custodial sentence with concurrent terms applied across all counts of the indictment. In addition to imprisonment, Harrison was ordered to complete 175 hours of unpaid community work and undergo 10 days of rehabilitation activity. Crucially, the court imposed a director disqualification order, barring him from managing or founding corporate entities within the UK commercial landscape.
Legal proceedings concerning Medicina Ltd as a corporate body remain active, with a dedicated sentencing date yet to be scheduled. Investigative reporting by outlets such as BBC News indicates that Harrison has severed his formal ties with the company, having left the organization prior to the conclusion of the trial.
The Scope of Compromised Equipment: Understanding the Devices
At the heart of the prosecution were specific categories of medical devices utilized extensively in vulnerable patient populations across the UK healthcare network. The devices in question—specifically enteral feeding pumps, gastrostomy button devices, and specialized blunt fill needles—are critical tools in clinical settings, often deployed in long-term care, nutritional support, and oncology wards.
Enteral feeding pumps are sophisticated electro-medical devices designed to deliver liquid nutrition directly into a patient’s gastrointestinal tract. Because these pumps operate continuously or under strict volumetric controls, any mechanical failure, calibration error, or electrical malfunction poses direct clinical risks, ranging from underfeeding to acute aspiration pneumonia. Gastrostomy button devices, surgically placed through the abdominal wall into the stomach, similarly require absolute material safety and biocompatibility standards to prevent tissue necrosis, infection, or device degradation in situ. Blunt fill needles, utilized widely in pharmacy and clinical prep rooms to draw medication from ampoules without generating sharps injuries, must adhere to rigid structural integrity metrics to ensure safe handling.
By affixing invalid CE markings to these products, Medicina Ltd effectively bypassed the independent conformity assessment procedures required under European regulatory frameworks. These assessments are designed to verify that medical technology meets stringent benchmarks for performance, risk management, and clinical safety before entering the commercial market. The absence of legitimate certification meant that the devices were deployed without verified independent assurance that they could perform safely under routine hospital conditions.
Official Responses and Regulatory Enforcement Perspectives
The resolution of the case drew strong statements from senior figures within the United Kingdom’s regulatory and prosecutorial bodies, emphasizing the zero-tolerance approach adopted toward healthcare fraud and regulatory evasion.
James Pound, the MHRA Executive Director of Innovation and Compliance, underscored the significance of the outcome in a public statement following the hearing. "This has been a long and complex investigation, and we’re glad to have a conclusion with this sentencing," Pound stated. "It demonstrates our commitment to taking robust enforcement action against those who try to bypass regulations that help keep patients safe. Healthcare professionals need to be able to trust that the medical devices they use have been properly assessed and meet the standards designed to protect patients."
Pound also paid tribute to the meticulous investigative efforts underpinning the multi-year prosecution. "I want to thank our MHRA investigators for their dedication and persistence over years, as well as our partners at the Crown Prosecution Service for helping bring this case to court."
Echoing these sentiments, Sarah Palace, a specialist prosecutor from the Crown Prosecution Service, highlighted the fraudulent nature of the enterprise and outlined ongoing efforts to strip the perpetrators of their ill-gotten gains. "The actions of Harrison and Medicina Limited were completely dishonest and they made substantial sales from their fraudulently labeled products," Palace noted.
Furthermore, the CPS confirmed that financial penalties would extend beyond the criminal sanctions imposed on Harrison personally. "CPS lawyers worked closely with the MHRA to prosecute this case, and we will continue to bring those who commit fraud to justice," Palace added. "We have also commenced confiscation proceedings under the Proceeds of Crime Act to recover any available funds from this criminal activity."
Broader Implications for Healthcare Procurement and Regulatory Compliance
The successful prosecution of Kenneth Harrison carries profound implications for medical device regulation, NHS procurement protocols, and corporate governance within the life sciences and healthcare supply sectors in the United Kingdom.
First and foremost, the case highlights vulnerabilities in supply chain transparency. Hospitals and clinical procurement teams operate under immense financial and operational pressures, frequently relying on manufacturer-provided documentation and compliance labeling to vet incoming medical technologies. When suppliers engage in fraudulent misrepresentation regarding regulatory approvals, the downstream detection mechanisms within hospitals can be severely tested. The MHRA’s decisive action serves as a stark warning to commercial suppliers that deceptive labeling practices will be met with severe criminal liabilities, including custodial sentences for corporate leadership.
Second, the timing of the case coincides with a broader evolution in the UK’s post-Brexit regulatory landscape. As the MHRA transitions toward independent domestic regulatory frameworks for medical devices—moving progressively away from legacy EU CE-marking dependencies toward the upcoming UK Conformity Assessed (UKCA) mark requirements—the necessity for verifiable, unimpeachable compliance data has never been more acute. Cases involving forged or invalid historical certifications reinforce the argument for heightened digital traceability, independent audits, and rigorous pre-market validation checks across all tiers of the national health procurement ecosystem.
Finally, the initiation of confiscation proceedings under the Proceeds of Crime Act (POCA) signals an aggressive financial deterrence strategy. By targeting the commercial profits generated through the sale of unapproved devices, regulatory and judicial authorities aim to eliminate the economic incentives associated with corporate regulatory non-compliance. As the legal proceedings regarding Medicina Ltd conclude in the coming months, the case will undoubtedly stand as a benchmark precedent for regulatory enforcement in the UK medical device industry for years to come.
